Comparing standard and low-dose continuous renal replacement therapy for acute kidney injury
A Randomized Controlled Study Investigating Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT - The "Ketzerei" Trial
This study tests whether using a standard dose or a lower dose of a kidney treatment can help critically ill patients with acute kidney injury recover better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 165 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität Münster Academic / other |
| Locations | 2 sites (Münster and 1 other locations) |
| Trial ID | NCT06021288 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of standard dose continuous renal replacement therapy (CRRT) versus low-dose CRRT in critically ill patients suffering from acute kidney injury (AKI). The research aims to determine if a controlled level of azotaemia can lead to improved renal recovery in these patients. By enrolling adult patients who require CRRT, the study will assess the outcomes associated with different dosing strategies of CRRT. The findings could provide insights into optimizing treatment protocols for AKI in critical care settings.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill adults aged 18 and older who are experiencing acute kidney injury and require continuous renal replacement therapy.
Not a fit: Patients who are chronically dependent on dialysis or have severe comorbid conditions such as chronic kidney disease or severe liver cirrhosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved renal recovery rates in critically ill patients with acute kidney injury.
How similar studies have performed: While there is ongoing research in the area of CRRT, this specific comparison of standard versus low-dose CRRT is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with AKI + in need of CRRT * Written informed consent Exclusion Criteria: * Chronic dialysis dependency * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73m² * severe liver cirrhosis (Child-pugh C) * severe acidosis (pH \< 7,20 at study enrolment) * severe hyperkalaemia (\> 6mmol/l) * Pregnancy or breastfeeding * persons held in an institution by legal or official order * Dependency on the investigator or center
Where this trial is running
Münster and 1 other locations
- University Hospital Münster — Münster, Germany (Recruiting)
- Universitätsklinikum Tübingen; Universitätsklinik für Anästhesiologie und Intensivmedizin — Tübingen, Germany (Recruiting)
Study contacts
- Study coordinator: Alexander Zarbock, MD
- Email: aki@anit.uni-muenster.de
- Phone: +492518347255
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.